Home > DARE Reviews > Choose which method for the chemotherapy...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews.

Choose which method for the chemotherapy of epithelial ovarian carcinoma: a meta-analysis

Review published: 2010.

Bibliographic details: Cui Y, Cui MH, Jia Y.  Choose which method for the chemotherapy of epithelial ovarian carcinoma: a meta-analysis. National Medical Journal of China 2010; 90(17): 1177-1180. [PubMed: 20646563]

Abstract

OBJECTIVE: To evaluate the differences of clinical efficacy between intraperitoneal and intravenous chemotherapy.

METHODS: The literature database was extensively searched to retrieve the randomized controlled trials with a relevance of study goal. The strict inclusion and exclusion criteria were formulated. And the original studies were selected. After a quality evaluation, the data were extracted. The Cochrane collaboration Revman 4.2 version software was used for meta-analysis.

RESULTS: Five clinical studies were included and there were a total of 1 229 eligible patients. Intraperitoneal chemotherapy and intravenous chemotherapy groups were compared: (1) 2 and 3-year progression-free survival (PFS) increased, 2, 3 and 5-year overall survival (OS) increased. The difference was significant enough so that definite conclusions could be drawn; (2) Among the six indicators of unpleasant chemotherapeutic effects (leucopenia, anemia, thrombopenia, GI tract reactions, neurotoxicity and fever), the occurrence of gastrointestinal reaction increased. The difference was significant enough so that definite conclusions could be drawn. And the remaining five indicators had no statistical significance so that definite conclusions could not be drawn.

CONCLUSIONS: For patients with epithelial ovarian cancer (Stages FIGOII-IV) undergoing previously a satisfactory tumor reduction surgery (postoperative residual lesions < 1 to 2 cm), intraperitoneal chemotherapy can improve their 2 and 3-year PFS rates and the 2, 3 and 5-year OS rates; Intraperitoneal chemotherapy has not reduced the side effects. But there is an elevated occurrence of gastrointestinal reactions.

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2014 University of York.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...